活力中国调研行丨守正创新让老字号药企“越活越年轻”

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has evolved from a state-owned deer farm established in 1957 to a modern enterprise with three major business segments: pharmaceuticals, finance, and health care, occupying an industrial park of 122 hectares, showcasing significant growth and innovation in the industry [1][3]. Group 1: Company Overview - Jilin Aodong operates 20 subsidiaries, primarily focused on pharmaceuticals, including six drug processing companies and five sales companies, which form the core production capacity of the company [3]. - The company holds 624 production approval numbers, with 312 for traditional Chinese medicine and 312 for chemical drugs, including 46 exclusive varieties and dosage forms [3]. Group 2: Financial Performance - Jilin Aodong anticipates a profit exceeding 1.2 billion yuan in the first half of the year, driven by the sustained performance of its three business segments [6]. - The investment return from Guangfa Securities, in which Jilin Aodong holds a 20.11% stake, is expected to grow by 40.69% year-on-year for the 2024 fiscal year [6]. Group 3: Business Strategy and Future Outlook - The company is expanding into the "big health" sector through subsidiaries focused on health technology and enzyme production, which are seen as new growth points [8]. - Jilin Aodong emphasizes technological innovation to foster new productive forces and accelerate industrial transformation, contributing to local employment and tax revenue [8].